returned a questionnaire whereas drug history was available for 175 of these patients. Sixty-seven percent (67%) of respondents were female, and 60% of all respondents had used cannabis before. The main indications for cannabis use were chronic pain (72.5%) and muscle cramp/stiffness (53.0%). Among the cannabis users, 42.0% suffered from multiple sclerosis and 11.0% were diagnosed with rheumatic diseases. The history of drug use showed a relatively frequent use of analgesics (36.6%) and psycholeptics (34.9%). Experiences with previous use of other cannabis products indicated that concomitant drug use could be decreased in 40.4% of the patients, remained the same in 48.6% and increased in 0.9%; in total 10.1% did not use any concomitant drugs. Most reported side effects of previous cannabis products were lethargy (42.5%) and dry mouth (38.1%). CONCLUSIONS: The main indications for prescription of medicinal cannabis were chronic pain and muscle cramp/stiffness; multiple sclerosis was the most frequently reported disease. The majority of patients had used other cannabis products before, resulting in a decrease in concomitant drug use in a substantial number of patients. Legalization did not cause an excessive increase of cannabis used, most likely to be explained by the more expensive drugs in the pharmacy compared to coffee shops.
PHP18 INTRODUCING THE 'FOURTH HURDLE' IN THE NEW EUROPEAN UNION MEMBER STATES: THE CASE OF HUNGARY
Gulácsi L 1 , Boncz I 2 , Drummond MF 3 1 Budapest University of Economic Sciences and Public Administration, Budapest, Hungary; 2 National Health Insurance Fund Administration, Budapest, Hungary; 3 University of York, York, North Yorkshire, UK OBJECTIVES: This paper outlines the current development of the "fourth hurdle" (i.e. requirement of effectiveness and costeffectiveness data for drug coverage policy decisions) in one of the new European Union member states, describes the needs and seeks to address some of the most important questions in this field. METHODS: The paper draws on international experiences and discusses some issues that a given jurisdiction needs to consider prior to introducing the "fourth hurdle" for pharmaceuticals. RESULTS: The "fourth hurdle" is very relevant to the new member states since many existing drugs are unevaluated and many new, expensive drugs are becoming available. On the other hand, the existing resources for health technology assessment, including economic evaluation, are quite limited. CONCLU-SIONS: The most important issue seems to be that the implementation of the "fourth hurdle" needs to be achieved in a way consistent with the limited resources for health economics analysis in the new member states. Specifically this means that, in setting priorities for drugs to be evaluated, additional criteria need to be applied. In particular, priority should be given to assessing drugs that have been evaluated in other countries, since this affords the opportunity to adapt existing studies or models to the situation of the new European Union member states. Opportunity exists to learn from experiences and mistakes in other countries and to find ways to make optimal use of evidence produced elsewhere and processes, which are already thoroughly tested. Given these restrictions, recommendations will be made on how to implement results of economic evaluation, using health economics as a tool to support reimbursement of medicines as a case study.
PHP19

EFFECTS OF DEVOLUTION OF SUBSIDIES FOR PHARMACEUTICALS IN SWEDEN
Bergstrom G, Karlberg I Goteborg University, Gothenburg, Sweden OBJECTIVES: In this study, the effects of devolution of subsidies for pharmaceuticals from the state to the regional health authorities-counties-in Sweden were studied. The aim of the reform in 1998 was to cut the escalating costs associated with risk sharing mechanisms on a national level as well as the third party payer principles. METHODS: The documentation was studied and the history of development and the current opinions were analysed from interviews in nine counties, selected based on their method of devolution. RESULTS: Two main principles were found: either a population-based responsibility for costs; family medicine in primary care was responsible for costs of drugs classified as "basic" (80%) regardless of prescriber, in addition hospital departments were responsible for "special drugs" regardless of prescriber. The other model was a prescriber-based responsibility; each unit of care was responsible for costs of its own prescribing. CONCLUSIONS: Incentives for cost containment are strongest in the prescriber-based models. Integration of drug costs in overall Health Care costs, service to patients and dialogue between providers are supported by the population-based models.
PHP20 PROPER DRUG MANAGEMENT IN PHARMACY-THE ROLE OF PHARMACOECONOMICS AS PERCEIVED BY POLISH PHARMACISTS
Czech M 1 , Turczynski R 2 , Pachocki R 1 1 Servier Polska, Warsaw, Poland; 2 Warsaw University of Technology, Warsaw, Poland On one hand, direct usage of pharmacoeconomic analyses in contemporary pharmacy practice seems to be limited, on the other hand correct communication with patients may benefit from promotion of rational pharmacotherapy, which stems from both doctors' decisions (prescribed drugs) and financial abilities of patients (especially when patient's co-payment is high). OBJECTIVES: To investigate the level of awareness among pharmacists concerning pharmacoeconomics in general, conducting and application of pharmacoeconomic analyses, activities focused on proper drug management (out-patient formularies, drug monitoring utilization systems, prescribing behaviour), etc. METHODS: Managers of 50 randomly selected pharmacies in Poland were interviewed. RESULTS: At the moment, drug costs, experts' opinion, personal opinion and drug efficacy are the most important sources of information. However, in an ideal situation the order should be different: efficacy, expert opinions and costs. Lack of governmental agencies' regulations on pharmacoeconomic evaluations, limited access to standarised cost data and low reliability of existing results of studies are listed among the main drawbacks in application of pharmacoeconomic study results. Wider use of pharmacoeconomics may be due to the creation of national cost databases in Health Care and introduction of transparent evaluation criteria. Societal and patient's viewpoint were indicated as the most appropriate where 87% of respondents declared the need to expand their knowledge in the field, 48% supported the idea of the creation of outpatient formularies, 42% were opposed, 65% confirmed the necessity of introduction of central drug usage monitoring systems, 65% of pharmacists claimed that they should inform GP's that their patients are unable to purchase a prescribed drug (co-payment is too high, need for substitution) and 75% thought that discussing economic aspects of treatment with patients was justified. CONCLUSIONS: Knowledge in pharmacoeconomics among pharmacists may lead to a deeper engagement of this group of professionals in a more appropriate management of drugs.
PHP21 QUALITY ASSESSMENT OF AN AMBULATORY CARE CLINIC BASED COLLABORATIVE CARE APPROACH FOR ACHIEVING THERAPEUTIC GOALS
Brown LM 1 , Isetts B 2 1 University of Tennessee, Memphis, TN, USA; 2 University of Minnesota, Minneapolis, MN, USA OBJECTIVES: The objectives of this study were to: 1) assess the quality of patient care provided by 6 Medication Therapy Management (MTM) pharmacists who were working collaboratively with physicians in 6 ambulatory care clinics in the Minneapolis, MN metropolitan area; and 2) determine the MTM pharmacists' ability to identify and resolve drug therapy problems. METHODS: The quality of therapeutic determinations made by pharmacists within this collaborative practice of MTM was studied using a 9-member panel of physicians (6) and pharmacists (3). The panel reviewed the care provided to nine randomly selected patient records from the 286 MTM patients who were Blue Cross/Blue Shield Blue Plus members. A structured implicit review process was used by the reviewers to specify their level of agreement with the therapeutic decisions made by the MTM pharmacists. The reviewers used a 7-point Likert scale to specify their level of agreement with each therapeutic decision. RESULTS: There were 6444 therapeutic review determinations made by the review panel. The 9 reviewers expressed agreement with 90.7% of the decisions. They expressed disagreement with only 2.8% of the decisions. For each therapeutic decision, twothirds or more of the reviewers agreed with the decision made in 99.9% of the cases. There was no difference in the mean ratings of the 9 patients based on an ANOVA (p = 0.906). Regarding drug therapy problems (DTP's), there were 20 DTP's identified during the initial patient visits. All but 5 DTP's were resolved by the second visit. CONCLUSIONS: The decisions made by MTM practitioners working in collaboration with physicians are clinically credible based on the ratings and comments of a peer review panel. This study provides information on the quality of care provided by pharmacists in the collaborative practice of medication therapy management.
PHP22 MEDICATION AND SOCIO-ECONOMIC STATUS IN A POPULATION-BASED COHORT STUDY
Moebus S 1 , Dragano N 2 , Weyers S 2 1 Medical Faculty, University of Duisburg-Essen, Essen, Germany; 2 University of Düsseldorf, Düsseldorf, Germany OBJECTIVES: Presently, statements on associations of socioeconomic status (SES) and use of medication are based on few and contradictory empirical data. Within the framework of the ongoing Heinz Nixdorf Recall study (HNRS), we can examine medication use and SES in detail. METHODS: The HNRS is a population-based cohort study to assess the predictive value of new risk factors for coronary artery disease. A random sample of 4518 men and women aged 45-74 years was recruited from the German cities of Bochum, Essen, and Mülheim between 2000-2003. We assessed the seven-day prevalence of any medication-use from 4519 subjects. Age, gender, highest school degree, highest professional training and income served as determinants of medication prevalence. Logistic regressions were used to estimate multivariate associations. RESULTS: A total of 11,500 drugs were taken by 3449 (76%) subjects, with ACE-inhibitors (9%), beta-blockers (8%), sexual hormones (6%), and statins (5%) ranked first. As expected, the prevalence of drug use increased with age, women reported a higher use than men (83 vs. 70%). For participants with the lowest compared to participants with the highest professional training an odds ratio (OR) of 2.04 (95% CI: 1.60-2.60) for taking medication was calculated. Adjusted for age and gender, this significant difference between social classes disappeared. Otherwise, gender specific analyses showed an age-adjusted OR for women with the lowest educational level of 2.0 (1.31-3.05) compared to women with the highest educational level and for men a higher use of psychopharmaceutics in the lowest compared the highest income group (1.92; 1.02-5.05). CONCLUSIONS: The association of SES on drug use is still not clear and seems to alter with the construct of social status, gender and drug groups. In particular, the challenging task to differentiate between the influence capability of SES on medication, medication on health/disease and vice versa has to be considered.
PHP23
ANALYSIS OF CLINICAL INTERVENTION DOCUMENTATION BY PHARMACISTS
Steimle T, Meier K, Melzer S LBK Hamburg, Hamburg, Germany OBJECTIVES: At LBK Hamburg, pharmacists started 1995 with patient orientated drug distribution named PAV (Patientenbezogene Arzneimittel Versorgung). In 2004 nearly 1300 patients in 48 wards are served daily with the Unit Dose System. Every patient's medication profile is recorded electronically. All medication orders are reviewed by pharmacists prior to delivering medication. In this way continuing pharmaceutical consultation is linked with the routine process of drug therapy. Medication errors and resulting costs have been reduced, acceptance of guidelines has been increased. On the base of ex-ante controlling and pharmacoeconomic consultation decreasing of costs should be reached. METHODS: On the base of the Problem-Intervention-Documentation-System (PI-Doc) of Humbold University, Berlin the system was developed specifically for hospitals. The goal was to analyse pharmaceutical interventions on medication errors and the rational use of drugs. For a period of two months all interventions were recorded by pharmacists. RESULTS: In the 2 months of the study 3010 interventions were recorded. A total of 2035 (67.6%) of the interventions are categorized as medication errors, including anamnesis and documentation errors and 975 (32.4%) of the recorded interventions are associated with optimization of drug therapy and cost-effective use of drugs. In this category, the main part was the successful adoption of the patients medication to the specific formulary of the hospital (24.5% (738)). Decreasing the number of special drug orders which are linked with extra process cost, the saved direct cost has been calculated. CONCLUSIONS: Pharmacists have a valuable role in preventing medication errors, improve patient care and cost-effective use of drugs. The analysis of pharmaceutical interventions highlights trends and patterns in prescription and medication errors. These results are to be used to improve effectiveness of pharmacists involvement in preventing medication errors and economic outcomes.
